What is Benign Prostatic Hyperplasia Treatment Market?
Benign prostatic hyperplasia (BPH) is a prostate gland enlargement causing uncomfortable urinary symptoms, such as blocking the flow of urine out of the bladder. It may also cause bladder, urinary tract, or kidney-related issues. Benign prostatic hyperplasia is a common problem that affects the quality of life in approximately one-third of men older than 50 years. It is estimated that around 30 million men have symptoms related to BPH. There are numerous effective treatments available for BPH such as medications, minimally invasive therapies, and surgery. BPH treatment depends upon the size of the prostate, age, overall health, and amount of discomfort.
The market study is being classified by Type (Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis)), Minimally invasive or surgical therapy, Laser therapy, Embolization and Others) and major geographies with country level break-up.
GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Abbott (United States), Boston Scientific Corporation (United States), Allergan plc (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Asahi Kasei Corporation (Japan), Boehringer Ingelheim (Germany), Astellas Pharma, Inc. (Japan), Sanofi S.A. (France), Merck & Co., Inc. (United States) and Olympus Corporation (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Teleflex Incorporated (United States) and Endo International plc (Ireland).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Benign Prostatic Hyperplasia Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Benign Prostatic Hyperplasia Treatment market by Type, Application and Region.
On the basis of geography, the market of Benign Prostatic Hyperplasia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Benign Prostatic Hyperplasia
- Rise in the Number of Hospitals and Clinics
- Technological Advancements in The Medical Science
- Less Awareness about Benign Prostatic Hyperplasia Treatment among People
- Growing Geriatric Population Worldwide
- Growth in the Healthcare Industry Worldwide
- Lack of Healthcare Infrastructure in Underdeveloped Countries
Market Leaders and some development strategies
In June 2019, Pfizer Inc. and Array BioPharma Inc. had announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
Key Target AudienceBenign Prostatic Hyperplasia Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase